Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2189830 | 1.00 | SLC6A4 (0.43) | SLC6A4SLC6A3SLC6A2MAPTPKM | |
| SCHEMBL2189838 | 1.00 | SLC6A4 (0.43) | SLC6A4SLC6A3SLC6A2MAPTPKM | |
| SCHEMBL2188615 | 0.90 | MAPT (0.45) | SLC6A4SLC6A3SLC6A2MAPTPKM | |
| SCHEMBL2188612 | 0.90 | MAPT (0.45) | SLC6A4SLC6A3SLC6A2MAPTPKM | |
| SCHEMBL2188619 | 0.90 | MAPT (0.45) | SLC6A4SLC6A3SLC6A2MAPTPKM | |
| SCHEMBL2189600 | 0.90 | MAPT (0.45) | SLC6A4SLC6A3SLC6A2MAPTPKM | |
| SCHEMBL2189606 | 0.90 | MAPT (0.45) | SLC6A4SLC6A3SLC6A2MAPTPKM | |
| SCHEMBL2189794 | 0.87 | MAPT (0.56) | SLC6A4SLC6A3SLC6A2MAPTPKM | |
| SCHEMBL2189798 | 0.87 | MAPT (0.56) | SLC6A4SLC6A3SLC6A2MAPTPKM | |
| SCHEMBL2189791 | 0.87 | MAPT (0.56) | SLC6A4SLC6A3SLC6A2MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2361246-A1 | OXOPIPERIDINYL AND PYRANYL SULFONAMIDES AS AMPA POTENTIATORS | Pfizer Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20110172297-A1 | Oxopiperdinyl And Pyranyl Sulfonamides and Pharmaceutical Compositions Thereof | PFIZER INC | 2011-07-14 | — | — | US | disclosed |
| WO-2010038167-A1 | OXOPIPERIDINYL AND PYRANYL SULFONAMIDES AS AMPA POTENTIATORS | PFIZER INC. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172297-A1 | Oxopiperdinyl And Pyranyl Sulfonamides and Pharmaceutical Compositions Thereof | GRIK5, GABRE, GRIK2 | SLC6A4 629/4885SLC6A3 759/4885SLC6A2 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.